Sanofi Ventures has invested in biotechnology company Lifordi Therapeutics, bringing Lifordi’s total financing round up to $112 million.  The funding is set to be used to support an ongoing Phase I study in Rheumatoid Arthritis (RA) by evaluating LFD-200, an ADC delivering a potent glucocorticoid (GC) directly to immune cells. It also provides for Chemistry Manufacturing and Controls (CMC) […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!